Appropriateness Of Proton Pump Inhibitors Prescription In Patients Admitted To A Malaysian Tertiary Hospital

Then Ru Fah, Tan Yi Jun, Pan Yan, Chieng Jin Yu



Proton pump inhibitors (PPIs) are one of the commonest drug prescribed, however it is not without risk of adverse effects especially if the usage is inappropriate. We aimed to evaluate the frequency, indications and appropriateness of PPIs prescription among the medical inpatients, Serdang Hospital, which is a tertiary hospital in Malaysia.

Materials and Methods:

This is a retrospective cross sectional study consisting of 4953 patients admitted to medical ward from 1st July 2016 to 31st March 2017, and their database were further analysed by Statistical Package for the Social Sciences for Windows (IBM SPSS Statistics 17.0). Unpaired t-test was performed to analyze the data collected. P < 0.05 (two-tailed) is considered significant. Their indications were cross-referenced against the indications adapted from the United States Food and Drug Administration (FDA).


23.9% (1184/4953) of inpatients were using PPIs, and 63% (746/1184) of them recently started on PPI in the ward, with mean age of 59.7 years. More male patients were commenced on PPIs during hospitalization (P value < 0.05). Based on the FDA guideline, only 21.8% patients were indicated, 32.2% were borderline indicated, and 46.0% patients were not indicated in prescribing PPIs. Stress ulcer prophylaxis was the commonest indication, while anaemia with no evidence of gastrointestinal bleed was the main non-indication in starting PPIs. Only 11% of patients had performed the oesophago-gastro-duodenoscopy (OGDS) during the hospital stay.


A majority of inpatients were inappropriately prescribed PPIs according to FDA guideline. More efforts should be initiated to improve the current situation of PPIs overutilization in Malaysia.


Keywords: Proton pump inhibitor – Overutilization – Appropriateness - Malaysia


Proton pump inhibitor – Overutilization – Appropriateness - Malaysia

Full Text:



Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting,2002-2009. PLoS One. 2013; 8(2):e56060.

Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. AM J Manag Care.2010; 16:e228-234.

Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 2010; 49:2561-2568.

Muhammad H, Faiza Y, Syed KMG, Fahd A, Frank W. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. JRSM Short Rep. 2013;4:2042533313497183.

Bustamante Robles KY, Ticse AR, Canepa RIF, Costta HCG, Vasquez KS, Soto AL, Sosa VH. Frequency of proton pump inhibitor prescription based in clinical practice guidelines in hospitalized patients in two academic hospitals in Lima, Peru. Rev Gastroenterol Peru. 2012; 32:44-49.

Christopher Chia TW, Lim WP, Charles Vu KF. Inappropriate use of proton pump inhibitors in a local setting. Singapore Med J. 2014; 55:363-366.

Lim L, Mohamed Izham MI. Selection of proton pump inhibitors (PPIS) for formulary inclusion using an objective scoring system in Malaysia. J Appl Pharm Sci. 2012; 2:17–24.

Mohamed HE , Mohamad HNM, Amirul H, Rabiatul NK. Evaluation of Proton Pump Inhibitors Prescribing among Non-Critically Ill Hospitalized Patients in a Malaysian Tertiary Hospital. Journal of Applied Pharmaceutical Science 7 (12); 2017:077-083.

Kirubakaran R and Loo JH. The Appropriateness of Acid Suppressive Medications’ Use in a Tertiary Hospital in Kedah. Ijppr.Human, 2016; 6 (4):719-728.

Gupta R, Garg P, Kottoor R, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010; 103:207–11.

Ali T, Roberts DN, Tierney WM. Long-term Safety Concerns with Proton Pump Inhibitors. Am J Med. 2009; 122:896–903.

Orlaith B. Kelly, Catherine Dillane, Stephen E. Patchett, Gavin C. Harewood, Frank Murray. The Inappropriate Prescription of Oral Proton Pump Inhibitors in the Hospital Setting: A Prospective Cross-Sectional Study. Dig Dis Sci. 2015 Aug; 60(8): 2280-6.

American Geriatric Society 2015 Beers Criteria Update Expert Panel (2015). American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of American Geriatric Society, 63, 2227-2246.

Kurata JH, Haile BM, Elashoff JD. Sex differences in peptic ulcer disease. Gastroenterology. 1985 Jan; 88(1 Pt 1):96-100.

De Martel C, Parsonnet J. Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys. Dig Dis Sci. 2006 Dec; 51(12):2292-301.

Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007; 102:2047-2056.

Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012 Jul; 107(7):1011-9.

Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci N. Y. 2011; 56(4): 931-950.

Chubineh S, Birk J. Proton pump inhibitors: the good, the bad, and the unwanted. South Med J. 2012; 105(11): 613-618.

Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296:2947-2953.

Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004; 292:1955-1960.

Eurich DT,Sadowski CA,Simpson SH,Marrie TJ,Majumdar SR.Recurrent community‐acquired pneumonia in patients starting acid‐

suppressing drugs.Am J Med. 2010; 123(1): 47–53.

Herzig SJ,Howell MD,Ngo LH,Marcantonio ER.Acid‐suppressive medication use and the risk for hospital‐acquired pneumonia.JAMA.2009;301(20):2120–2128.

Polasek TM, Lin FP, Miners JO et al. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol2011;71:727–736.

Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008; 51:256–260.

Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011; 89:65–74.

Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010; 122:2619–2633.

Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010; 16:122-129.

Valori RM, Brown CM, Strangeways P, Bradburn M. Reducing community dyspepsia drug costs: a controlled trial. Gut. 2001; 49:495-501.

Cardin F, Zorzi M, Bovo E, Guerra C. Bandini F, Polito D, Bano F, Grion AM, Toffanin R. Effect of implementation of a dyspepsia and Helicobacter pylori eradication guideline in primary care. Digestion. 2005; 72:1-7.


  • There are currently no refbacks.

Copyright (c) 2019 Then Ru Fah, Tan Yi Jun, Pan Yan, Chieng Jin Yu

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.